Eli Lilly & Co. has agreed to pay up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment targeting heart disease. The acquisition will allow Eli Lilly to bring this innovative therapy to market, aiming to offer a one-and-done solution for patients with heart conditions. This deal marks a significant investment in the biotech sector and is expected to drive growth for both companies involved.
Source: https://www.marketwatch.com/story/this-one-and-done-heart-disease-treatment-just-got-a-1-3-billion-endorsement-from-eli-lilly-5c163b61